Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2013 Dec;10(12):686-7.
doi: 10.1038/nrurol.2013.269. Epub 2013 Nov 26.

Prostate cancer: Intermediate efficacy end points to assess modern therapies

Ravi A Madan  1 , James L Gulley
Affiliations
Comment

Prostate cancer: Intermediate efficacy end points to assess modern therapies

Ravi A Madan et al. Nat Rev Urol. 2013 Dec.

Abstract

A retrospective, single institution study of 450 men with biochemical recurrence after radical prostatectomy included 140 men with androgen deprivation therapy deferred until metastatic disease onset. Metastasis-free survival was an independent predictor of overall survival. This research highlights the need to develop appropriate intermediate end points to expedite prostate cancer treatment.

PubMed Disclaimer

Conflict of interest statement

Competing interests

The authors declare no competing interests.

Comment on

References

    1. Schweizer MT, Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann. Oncol. . - DOI - PMC - PubMed
    1. Smith MR et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379, 39–46 (2012). - PMC - PubMed
    1. Sonpavde G & Palapattu GS Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials. Expert Rev. Anticancer Ther 10, 439–450 (2010). - PubMed
    1. Eastham JA, Kelly WK, Grossfeld GD, Small EJ & Cancer & Leukemia Group B. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 62 (Suppl. 1), 55–62 (2003). - PubMed
    1. Antonarakis ES et al. Changes in PSA kinetics predict metastasis-free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials. Cancer 118, 1533–1542 (2012). - PMC - PubMed